Кардиология и сердечно-сосудистая хирургия, 1, 2017. Выпуск 2

Coll Cardiol.
2007;50:768-777.
15. Gheorghiade M, Konstam MA, Burnett JC Jr et al. Efficacy of 
Vasopressin Antagonism in Heart Failure Outcome Study With 
Tolvaptan (EVEREST) Investigators. Short-term clinical effects 
of tolvaptan, an oral vasopressin antagonist, in patients hospital-
ized for heart failure: the EVEREST Clinical Status Trials. JAMA. 
2007;297:1332-1343.
16. Goldberg RJ, Gurwitz JH, Saczynski JS, et al. Comparison of 
medication practices in patients with heart failure and preserved 
versus those with reduced ejection fraction (from the Cardiovas-
cular Research Network [CVRN]). Am J Cardiol. 2013;111:1324-
1329.
17. Massie BM, Carson PE, McMurray JJ. Irbesartan in patients with 
heart failure and preserved ejection fraction. N Engl J Med. 
2008;359:2456-2467. 
18. Massie BM, Carson PE, McMurray JJ. Irbesartan in patients with 
heart failure and preserved ejection fraction. N Engl J Med. 
2008;359:2456-2467. 
19. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines 
for the diagnosis and treatment of acute and chronic heart failure 
2012. The Task Force for the Diagnosis and Treatment of Acute 
and Chronic Heart Failure 2012 of the European Society of Cardi-
ology. Developed in collaboration with the Heart Failure Associa-
tion (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
20. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs do-
butamine for patients with acute decompensated heart failure: the 
SURVIVE randomized Trial. JAMA. 2007;297:1883-1891. 
21. Metaanalysis Global Group in Chronic Heart Failure (MAG-
GIC). The survival of patients with heart failure with preserved or 
reduced left ventricular ejection fraction: an individual patient 
data metaanalysis. Eur Heart J. 2012;33:1750-1757.
22. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on car-
diac, renal, and hepatic biomarkers in the Relaxin in Acute Heart 
Failure (RELAX-AHF) development program: correlation with 
outcomes. J Am Coll Cardiol. 2013;61:196-206.
23. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of ne-
siritide in patients with acute decompensated heart failure. N Engl 
J Med
. 2011;365:32-43.
ОРИГИНАЛЬНЫЕ СТАТЬИ

33
КАРДИОЛОГИЯ И СЕРДЕЧНО-СОСУДИСТАЯ ХИРУРГИЯ, 1, 2017. ВЫПУСК 2 
24. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodi-
esterase-5 inhibition on exercise capacity and clinical status in 
heart failure with preserved ejection fraction: a randomized clini-
cal trial. JAMA. 2013;309:1268-1277.
25. Summers RL, Amsterdam E. Pathophysiology of acute decom-
pensated heart failure. Heart Fail Clin. 2009;5:9-17. 
26. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant 
human relaxin-2, for treatment of acute heart failure (RELAX-
AHF): a randomized, placebo-controlled trial. Lancet. 
2013;381:29-39. 
27. Teichman SL, Unemori E, Teerlink JR. Relaxin: review of biology 
and potential role in treating heart failure. Curr Heart Fail Rep. 
2010;7:75-82.
28. Yancy CW, Lopatin M, Stevenson LW, et al. ADHERE Scientific 
Advisory Committee and Investigators. Clinical presentation, 
management, and in-hospital outcomes of patients admitted with 
acute decompensated heart failure with preserved systolic func-
tion: a report from the Acute Decompensated Heart Failure Na-
tional Registry (ADHERE) database. J Am Coll Cardiol. 
2006;47:76-84. 
29. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in 
patients with chronic heart failure and preserved left-ventricular 
ejection fraction: the CHARM-Preserved Trial. Lancet. 
2003;362:777-781.